AFP16h
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Reduce the ALYFTREK dosage with concomitant use of strong or moderate CYP3A inhibitors Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines ...